Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768144 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00768144 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT00768144, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor.
Interventions
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768144
The ClinicalTrials.gov registry entry for NCT00768144 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib is the first listed.
NCT00768144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768144 about?
NCT00768144 is a clinical study titled "Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma". The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor.
What is the current status of trial NCT00768144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-09. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00768144?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00768144?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.